What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Endocrinology
His primary areas of study are Internal medicine, Endocrinology, Endothelium, Cardiology and Nitric oxide.
His Internal medicine research integrates issues from Fasudil and Rho-associated protein kinase.
His work is dedicated to discovering how Endocrinology, Pulmonary hypertension are connected with Hypoxia and other disciplines.
His Endothelium research is multidisciplinary, incorporating elements of Vasodilation, Biochemistry, Bradykinin, Pharmacology and Endothelium-derived hyperpolarizing factor.
His Angina, Ejection fraction, Chest pain and Ischemia study, which is part of a larger body of work in Cardiology, is frequently linked to Vasospasm, bridging the gap between disciplines.
His Nitric oxide study which covers Mesenteric arteries that intersects with Dihydrobiopterin and Biopterin.
His most cited work include:
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (3050 citations)
- Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice (631 citations)
- Endothelial dysfunction and vascular disease (607 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Cardiology, Endocrinology, Heart failure and In patient.
Internal medicine is a component of his Nitric oxide, Myocardial infarction, Endothelium, Ejection fraction and Pulmonary hypertension studies.
The Endothelium study combines topics in areas such as Endothelium-derived hyperpolarizing factor and Vasodilation.
Hiroaki Shimokawa usually deals with Cardiology and limits it to topics linked to In vivo and Pharmacology.
In his research on the topic of Endocrinology, Pathogenesis is strongly related with Rho-associated protein kinase.
His Heart failure research is multidisciplinary, relying on both Intensive care medicine and Hazard ratio.
He most often published in these fields:
- Internal medicine (68.81%)
- Cardiology (46.58%)
- Endocrinology (19.71%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (68.81%)
- Cardiology (46.58%)
- Heart failure (18.38%)
In recent papers he was focusing on the following fields of study:
Hiroaki Shimokawa mainly focuses on Internal medicine, Cardiology, Heart failure, In patient and Pulmonary hypertension.
His Internal medicine study frequently draws connections between related disciplines such as Endocrinology.
His work on Vasospastic angina, Chronic thromboembolic pulmonary hypertension, Artery and Angina as part of general Cardiology research is frequently linked to Chart, thereby connecting diverse disciplines of science.
His Heart failure study incorporates themes from Diabetes mellitus, Proportional hazards model, Atrial fibrillation and Intensive care medicine.
The study incorporates disciplines such as Hypoxia, Lung, Pulmonary artery, Hemodynamics and Pharmacology in addition to Pulmonary hypertension.
In his study, Rivaroxaban is strongly linked to Stroke, which falls under the umbrella field of Myocardial infarction.
Between 2015 and 2021, his most popular works were:
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (3050 citations)
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (508 citations)
- International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology (372 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cardiology
Hiroaki Shimokawa mainly investigates Internal medicine, Cardiology, Heart failure, Hazard ratio and Endocrinology.
His is doing research in Myocardial infarction, Pulmonary hypertension, Angina, Coronary artery disease and Stroke, both of which are found in Internal medicine.
His work on Ejection fraction, Artery and Coronary arteries as part of general Cardiology study is frequently linked to In patient, bridging the gap between disciplines.
His Hazard ratio research includes themes of Placebo, Prospective cohort study, Randomized controlled trial and Survival analysis.
As part of his studies on Endocrinology, Hiroaki Shimokawa often connects relevant subjects like Proinflammatory cytokine.
His studies deal with areas such as Microcirculation and Vascular smooth muscle as well as Endothelium.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
